A 20-year-old male shared his 4-month hair regrowth results using finasteride, minoxidil, nizoral, and dermarolling. Commenters noted improved hair density and the potential for further progress.
The user is trying RU58841, oral minoxidil, and dermarolling to combat hair loss caused by increased scalp testosterone after using finasteride and dutasteride. They plan to document their results.
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.
The user shared progress pictures showing hair improvement over four months using 1 mg finasteride and 5 mg minoxidil daily. They reported no significant side effects and plan to reduce the minoxidil dose once satisfied with the results.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
The user experienced some hair regrowth after 4 months of inconsistent use of topical finasteride and minoxidil, with no noticeable side effects. Others suggest trying oral finasteride and minoxidil for better consistency.
Hair loss treatments Finasteride, Dutasteride, Pyrilutamide, and RU58841 have different mechanisms of action. They can be used individually or stacked for better protection against hair loss.
A user shared their 4-month progress using a topical solution with 5% minoxidil and 0.1% finasteride, applied twice daily. They reported good results despite occasional missed applications.
The user has been using a topical solution of minoxidil 5% and finasteride 0.025% daily, along with dermastamping every two weeks and ketoconazole shampoo twice a week for four months. The treatment is for hair loss.
A user's progress with treating hair loss, using minoxidil, finasteride and microneedling. The user experienced impressive results after four months of treatment, and mentioned that stopping recreational drugs and losing weight helped their hair regrowth.
The user experienced significant hair regrowth and improved hair volume after 4 months of using oral dutasteride (0.5 mg) and minoxidil (2.5 mg) daily, eliminating the need for a second hair transplant. The user is now satisfied with the results and feels more confident.
A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.
An 18-year-old is experiencing positive hair regrowth results using 2.5mg minoxidil, 0.5mg finasteride daily, and dermarolling twice a week. They are satisfied with the progress and hope for continued improvement.
The conversation discusses a hair loss treatment regimen including finasteride, dutasteride, minoxidil, tretinoin, microneedling, and red light therapy. The user plans to update on progress after eight months.
A user shared their 4-year progress using topical minoxidil and 1mg finasteride daily for hair regrowth, noting plans to reduce finasteride due to minor side effects. They emphasized consistency as key to success, with noticeable improvements in hair density and color.
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
The user is using oral Minoxidil, oral Dutasteride, microneedling, and RU58841 for hair loss, noticing slow progress with small hairs appearing. They are inconsistent with microneedling frequency, sometimes doing it weekly or skipping weeks.
The post is about a user's hair loss progress using Minoxidil and dutasteride treatments. The conclusion is that the user has seen positive results after 5 months of treatment and has no regrets.
RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.
The conversation is about a person rapidly losing hair and seeking information on the availability of a new treatment called scube3, as they have experienced side effects from current treatments like Minoxidil and finasteride. They are hoping scube3 will be approved soon as they believe it's their only remaining option.
A user shared impressive hair regrowth results after 4 months using topical minoxidil, oral finasteride, and 3 PRP sessions. They plan to continue with these treatments and add dermastamping.
A user has been using Minoxidil and dermarolling for 4 months to treat hair loss, with some success. However, others suggest that without adding finasteride to the regimen, the hair regrowth may not last.
The user has been using a finasteride and minoxidil combo spray from Hims for four months, with positive results and no side effects. They apply four sprays nightly, targeting the crown and front of the scalp.
A user shared their positive hair regrowth results after 4 months using topical minoxidil, a 0.5 dermastamp once a week, and ketoconazole shampoo. Some responses suggest adding finasteride to maintain results, while others praise the effectiveness of the treatments used.
Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.
The conversation is about hair regrowth using finasteride and minoxidil, with users noting visible new hair growth and discussing dosages. Some users express encouragement and hope, while one advises against using finasteride.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.